StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
September 10, 2024 1:08 PM
Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
September 12, 2024 5:07 AM
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
September 10, 2024 11:41 AM
Form 8-K Viridian Therapeutics, For: Sep 10
September 10, 2024 7:11 AM
Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
September 10, 2024 7:02 AM
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
September 10, 2024 7:00 AM
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
September 9, 2024 4:01 PM
